Welcome to our dedicated page for Nephros news (Ticker: NEPH), a resource for investors and traders seeking the latest updates and insights on Nephros stock.
Nephros Inc. reports developments in water technology for medical and commercial markets, with emphasis on point-of-use filtration, waterborne pathogen risk reduction, and water management support. Company news commonly covers quarterly financial results, programmatic revenue trends, service offerings, customer education, and product adoption across healthcare facilities and other complex buildings.
Updates also include expansions of Nephros' water safety capabilities, regional market initiatives, and the Nephros Water Institute, an education effort focused on water quality, infection prevention, regulatory readiness, and emergency preparedness for compromised water events.
Nephros, a water technology company specializing in filtration solutions, announced it will release its fourth quarter and fiscal 2022 results on March 8, 2023, after market close. A conference call will follow at 4:30 PM ET. Participants can join via domestic access at 1 (844) 808-7106 or international access at 1 (412) 317-5285. An audio archive will be available post-call on Nephros' investor relations page. The company aims to enhance the human relationship with water by providing innovative filtration products and quality education, serving both healthcare and commercial markets.
Nephros, Inc. (Nasdaq: NEPH) reported preliminary revenue results for Q4 and full year 2022. Q4 net revenue is projected at $2.6 million, a 6% increase quarter-over-quarter but a 6% decline year-over-year. Full-year revenue stands at $10.0 million, down 2% compared to 2021. Despite challenges, the company saw sequential revenue growth and a record of 1,394 Active Customer Sites. Net cash flow improved, with a negative $500,000 in the second half versus $2.9 million in the first half. Nephros ended Q4 with $3.6 million cash.
Nephros, Inc. (Nasdaq: NEPH) reported third-quarter net revenue of $2.4 million, down 7% year-over-year. The company faced a net loss of $1.3 million, an increase from $0.8 million in Q3 2021, influenced by inventory reserve adjustments. Despite a revenue decline, Active Customer Sites rose 18% to a record 1,391. Nephros plans to sell its Pathogen Detection Systems business to cut quarterly expenses by $300,000 and strengthen its financial position. The company maintains a cash balance of $3.9 million, indicating no immediate need for capital raising.
Nephros, a leading water technology company, will announce its third-quarter financial results on November 2, 2022, after market close. A conference call is scheduled for 4:30 PM ET the same day, allowing participants to access the call domestically at 1 (844) 808-7106 or internationally at 1 (412) 317-5285. Interested parties can find an audio archive of the call on Nephros' Investor Relations page.
Nephros, Inc. (Nasdaq: NEPH) announced the sale of its Pathogen Detection Systems (PDS) business to BWSI, aiming to reduce cash burn by approximately $350,000 per quarter. The sale includes a seven-year earn-out provision based on gross profits of PDS products. For Q3 2022, Nephros expects net revenue of $2.5 million and an 18% year-over-year increase in active customer sites, reaching 1,391. The company aims for positive net cash flow by mid-2023, ending Q3 with $3.9 million in cash.
Nephros, Inc. (Nasdaq: NEPH) has successfully shipped 3,000 commercial water filters as part of an ongoing contract with Donastar Enterprises LLC and Tractor Beverage Co. This delivery marks a significant milestone following Nephros's approval as a vendor for a major Quick Service Restaurant (QSR) chain. CEO Andy Astor highlighted the positive momentum and potential for further national contracts, indicating growth in Nephros's commercial water filtration business.
Nephros, a water technology company, announced the appointment of Joe Harris to its Board of Directors on September 8, 2022. Harris, who has over 20 years of healthcare sales management experience, expressed enthusiasm about joining Nephros at a pivotal time for the company's growth and sales momentum. Nephros's President and CEO, Andy Astor, highlighted Harris's financial, sales, and marketing expertise. Nephros specializes in filtration and pathogen detection solutions aimed at both healthcare and commercial markets.
Nephros reported a consolidated net revenue of $2.9 million for Q2 2022, marking a 27% increase year-over-year. The water filtration segment generated $2.8 million, a 30% growth compared to the same quarter last year. Active customer sites reached 1,349, up 21%. Despite this revenue growth, Nephros faced a net loss of $1.1 million, consistent with the previous year. Efforts to optimize costs included price increases and operational adjustments, aiming for positive cash flow by mid-2023.
Nephros, Inc. (Nasdaq: NEPH), a leader in water technology solutions, will announce its second-quarter financial results on August 10, 2022, after market close. A conference call will follow at 4:30 PM ET, accessible by dialing 1 (844) 808-7106 for domestic calls and 1 (412) 317-5285 for international participants. A replay will be available until August 17, 2022. Nephros focuses on innovative filtration and pathogen detection technologies that serve healthcare and commercial markets, aiming to enhance water safety and management.
Nephros, Inc. (Nasdaq: NEPH) reported a preliminary revenue of $2.9 million for Q2 2022, marking a 27% increase year-over-year. The number of Active Customer Sites grew by 21% from 1,117 to 1,349. CEO Andy Astor expressed optimism regarding revenue growth, supported by a strong sales pipeline and an expense management plan aimed at achieving positive net cash flow within the next 12 months. The company ended the quarter with approximately $4.2 million in cash. Q2 results will be officially announced on August 10, 2022.